{"id":5611,"date":"2012-05-04T09:00:00","date_gmt":"2012-05-04T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/"},"modified":"2024-09-23T11:22:45","modified_gmt":"2024-09-23T11:22:45","slug":"nieuwe-immuuntherapie-in-ontwikkeling","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/","title":{"rendered":"Nieuwe immuuntherapie in ontwikkeling"},"content":{"rendered":"Wetenschappers van het King College in Londen ontwikkelen een nieuwe peptide immuuntherapie voor T1D. De groep heeft in beta cellen een aantal peptides ge\u00efdentificeerd die de auto-immuunreactie bij T1D lijken te triggeren. Men is nu bezig om geselecteerde onderdelen van deze eiwitten om te zetten in een vorm die de ontstekingsreactie niet veroorzaakt maar juist stopt. Deze cocktail, MultiPepT1De, hoopt men te kunnen omzetten in een geneesmiddel waarmee de auto-immuunreactie tegen beta cellen wordt gestopt terwijl de rest van het imuunsysteem intact blijft. In 2014 worden tests op vrijwilligers verwacht.\n\n<a href=\"http:\/\/www.healthcanal.com\/metabolic-problems\/28817-Work-starts-new-therapy-prevent-Type-diabetes.html\">Lees verder (Engelstalig)<\/a>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Wetenschappers van het King College in Londen ontwikkelen een nieuwe peptide immuuntherapie voor T1D. De groep heeft in beta cellen een aantal peptides ge\u00efdentificeerd die de auto-immuunreactie bij T1D lijken te triggeren. Men is nu bezig om geselecteerde onderdelen van deze eiwitten om te zetten in een vorm die de ontstekingsreactie niet veroorzaakt maar juist [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5611","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nieuwe immuuntherapie in ontwikkeling - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nieuwe immuuntherapie in ontwikkeling - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Wetenschappers van het King College in Londen ontwikkelen een nieuwe peptide immuuntherapie voor T1D. De groep heeft in beta cellen een aantal peptides ge\u00efdentificeerd die de auto-immuunreactie bij T1D lijken te triggeren. Men is nu bezig om geselecteerde onderdelen van deze eiwitten om te zetten in een vorm die de ontstekingsreactie niet veroorzaakt maar juist [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2012-05-04T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:45+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Nieuwe immuuntherapie in ontwikkeling\",\"datePublished\":\"2012-05-04T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\"},\"wordCount\":100,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\",\"name\":\"Nieuwe immuuntherapie in ontwikkeling - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2012-05-04T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nieuwe immuuntherapie in ontwikkeling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nieuwe immuuntherapie in ontwikkeling - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/","og_locale":"nl_NL","og_type":"article","og_title":"Nieuwe immuuntherapie in ontwikkeling - Breakthrough T1D","og_description":"Wetenschappers van het King College in Londen ontwikkelen een nieuwe peptide immuuntherapie voor T1D. De groep heeft in beta cellen een aantal peptides ge\u00efdentificeerd die de auto-immuunreactie bij T1D lijken te triggeren. Men is nu bezig om geselecteerde onderdelen van deze eiwitten om te zetten in een vorm die de ontstekingsreactie niet veroorzaakt maar juist [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/","og_site_name":"Breakthrough T1D","article_published_time":"2012-05-04T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:45+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Nieuwe immuuntherapie in ontwikkeling","datePublished":"2012-05-04T09:00:00+00:00","dateModified":"2024-09-23T11:22:45+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/"},"wordCount":100,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/","name":"Nieuwe immuuntherapie in ontwikkeling - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2012-05-04T09:00:00+00:00","dateModified":"2024-09-23T11:22:45+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/nieuwe-immuuntherapie-in-ontwikkeling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Nieuwe immuuntherapie in ontwikkeling"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5611"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5611\/revisions"}],"predecessor-version":[{"id":7304,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5611\/revisions\/7304"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}